Masuda Satoshi, Urabe Yuji, Hatsushika Yoshiki, Uda Takahiro, Sako Yukiko, Gurita Tomoyuki, Nakamura Takeo, Konishi Hirona, Ishibashi Kazuki, Takasago Takeshi, Tanaka Hidenori, Tsuboi Akiyoshi, Yamashita Ken, Hiyama Yuichi, Kishida Yoshihiro, Takigawa Hidehiko, Ishikawa Akira, Kuwai Toshio, Oka Shiro
Department of Gastroenterology, Hiroshima University Hospital, 1-2-3, Kasumi, Minamiku, Hiroshima, 734-8551, Japan.
Department of Clinical Research Center, Hiroshima University Hospital, Hiroshima, Japan.
Esophagus. 2025 Jun 15. doi: 10.1007/s10388-025-01136-5.
The precise indications for endoscopic submucosal dissection (ESD) in superficial spreading esophageal squamous cell carcinoma (SESCC) remain unclear. This study aimed to evaluate the lymph node metastasis rates and outcomes of ESD for SESCC lesions ≥ 50 mm, focusing on diagnostic accuracy, short-term outcomes, and long-term prognoses.
We retrospectively analyzed 79 patients who underwent ESD for SESCC between January 2011 and December 2018. We assessed lymph node metastasis rates, diagnostic accuracy, short-term outcomes, and long-term survival rates.
The en bloc resection and R0 resection rates were 98.7% and 94.9%, respectively. The diagnostic accuracy for tumor invasion depth was 74.7%. Lymph node metastasis occurred in 7.6% of patients, contributing to four primary cancer-related deaths (3.8%). Postoperative esophageal stenosis occurred in 65.6% of whole-circumference cases, with refractory stenosis requiring > 5 endoscopic balloon dilation procedures in 87.5% of affected patients. Overall survival (OS) rates were 91% at 3 years and 84% at 5 years, whereas recurrence-free survival (RFS) rates were 87% at 3 years and 80% at 5 years.
ESD for SESCC achieves high resection success rates but is associated with significant challenges, including refractory stenosis and lymph node recurrence, particularly in pLPM and pMM cases. Enhanced diagnostic and surveillance protocols, along with novel strategies for stenosis prevention, are necessary to improve outcomes and patient quality of life. Further comparative studies with surgical and chemoradiotherapy modalities are also needed.
浅表扩散型食管鳞状细胞癌(SESCC)内镜黏膜下剥离术(ESD)的确切指征仍不明确。本研究旨在评估ESD治疗病变≥50mm的SESCC的淋巴结转移率及治疗效果,重点关注诊断准确性、短期疗效和长期预后。
我们回顾性分析了2011年1月至2018年12月期间接受ESD治疗SESCC的79例患者。我们评估了淋巴结转移率、诊断准确性、短期疗效和长期生存率。
整块切除率和R0切除率分别为98.7%和94.9%。肿瘤浸润深度的诊断准确率为74.7%。7.6%的患者发生淋巴结转移,导致4例原发性癌症相关死亡(3.8%)。全周病变患者术后食管狭窄发生率为65.6%,87.5%的受累患者需要>5次内镜球囊扩张术治疗难治性狭窄。3年总生存率(OS)为91%,5年为84%;而3年无复发生存率(RFS)为87%,5年为80%。
SESCC的ESD取得了较高的切除成功率,但也面临重大挑战,包括难治性狭窄和淋巴结复发,尤其是在pLPM和pMM病例中。需要加强诊断和监测方案,以及预防狭窄的新策略,以改善治疗效果和患者生活质量。还需要与手术和放化疗方式进行进一步的比较研究。